Recently stock market analysts have updated their consensus ratings on shares of Aurinia Pharmaceuticals Inc (AUPH). The latest broker reports which are currently outstanding on Monday 9th of May state 0 analysts have a rating of “strong buy”, 0 analysts “buy”, 0 analysts “neutral”, 0 analysts “sell” and 0 analysts “strong sell”.

Most recent broker ratings

02/08/2016 – Aurinia Pharmaceuticals Inc had its “outperform” rating reiterated by analysts at FBR Capital Markets. They now have a USD 9 price target on the stock.

11/16/2015 – Aurinia Pharmaceuticals Inc had its “buy” rating reiterated by analysts at Canaccord Genuity.

05/21/2015 – Aurinia Pharmaceuticals Inc was downgraded to “sell” by analysts at Zacks.

05/08/2015 – Aurinia Pharmaceuticals Inc was upgraded to “buy” by analysts at MLV & Co. They now have a USD 9 price target on the stock.

02/02/2015 – Leerink Swann began new coverage on Aurinia Pharmaceuticals Inc giving the company a “outperform” rating. They now have a USD 8 price target on the stock.

Aurinia Pharmaceuticals Inc has a 50 day moving average of 2.93 and a 200 day moving average of 2.59. The stock’s market capitalization is 80.39M, it has a 52-week low of 1.42 and a 52-week high of 4.37.

The share price of the company (AUPH) was down -8.79% during the last trading session, with a high of 2.71 and the volume of Aurinia Pharmaceuticals Inc shares traded was 106687.

View other investors thoughts on Aurinia Pharmaceuticals Inc on our new Stock Talk discussion platform. Sign up for free to contribute to the community and view research provided from other investors for any stock listed on the LSE, NYSE or NASDAQ.